Abiopharma

Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

Bruker - Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction

New Form 6-K - ASTRAZENECA PLC Filed: 2025-06-24 AccNo: 0001654954-25-007315 Size: 62 KB

Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema

Tilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic Use

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention

New Form 8-K - Nuvalent, Inc. Filed: 2025-06-24 AccNo: 0000950170-25-089213 Size: 204 KB Item 8.01: Other Events

New Form 6-K - Haleon plc Filed: 2025-06-24 AccNo: 0001654954-25-007311 Size: 34 KB